相似文献
1
Ethics and the standards of prevention in HIV prevention trials.
AIDS. 2010 Sep 10;24(14):2298-9; author reply 2299-300. doi: 10.1097/QAD.0b013e32833d4364.
2
Response to Open Peer Commentaries on "Relative versus absolute standards for everyday risk in adolescent HIV prevention trials: expanding the debate".
Am J Bioeth. 2011 Jun;11(6):W1-3. doi: 10.1080/15265161.2011.578477.
3
Uniqueness, exploitation, and relative risk standards in adolescent research.
Am J Bioeth. 2011 Jun;11(6):23-5. doi: 10.1080/15265161.2011.568587.
4
Back to the rough ground: working in international HIV prevention as ethical debates continue.
IRB. 2003 Mar-Apr;25(2):11-3.
5
(Un)risky business: adolescents and HIV prevention trials.
Am J Bioeth. 2011 Jun;11(6):17-9. doi: 10.1080/15265161.2011.568585.
6
Minimal risk remains an open question.
Am J Bioeth. 2011 Jun;11(6):25-7. doi: 10.1080/15265161.2011.568579.
7
Why we don't need a relative risk standard for adolescent HIV vaccine trials in South Africa.
Am J Bioeth. 2011 Jun;11(6):21-2. doi: 10.1080/15265161.2011.566671.
8
Regulating "higher risk, no direct benefit" studies in minors.
Am J Bioeth. 2011 Jun;11(6):29-31. doi: 10.1080/15265161.2011.566669.
9
The concept of minimal risk: the need for better guidance on the ethics review process.
Am J Bioeth. 2011 Jun;11(6):27-9. doi: 10.1080/15265161.2011.568584.
10
A relative standard for minimal risk is unnecessary and potentially harmful to children: lessons from the Phambili trial.
Am J Bioeth. 2011 Jun;11(6):14-6. doi: 10.1080/15265161.2011.568588.
引用本文的文献
1
The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials.
HIV Clin Trials. 2014 Sep-Oct;15(5):185-98. doi: 10.1310/hct1505-185.
2
Stakeholder views of ethical guidance regarding prevention and care in HIV vaccine trials.
BMC Med Ethics. 2014 Jun 30;15:51. doi: 10.1186/1472-6939-15-51.
Zotero 插件